| The Company was incorporated as a private limited company `Alkem Laboratories Private Limited' on August 8,1973 at Patna under the Companies Act, 1956 and subsequently became a deemed public limited company under section 43A(2) of Companies Act, 1956 on October 26, 1988. Pursuant to the Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of the Company was changed to `Alkem Laboratories Limited' with effect from October 26, 1988. the registered office was originally located at `Exhibition Road, Patna - 800 001, Bihar, India'. the Company filed Company Petition No. 356(17)/ ERB/ 2007 before the Company Law Board, Eastern Region Bench at Kolkata for shifting the registered office of the Company from the State of Bihar to the State of Maharashtra, as approved by a special resolution at its extra-ordinary general meeting held on January 29, 2007. The Company Law Board, Eastern Region Bench at Kolkata passed an order dated July 30, 2007 whereby it confirmed the alteration of the situation clause in the Memorandum of Association, from the State of Bihar to the State of Maharashtra. Pursuant to the order, the registered office of the Company was shifted to `Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013, Maharashtra, India' with effect from August 2, 2007.
Major Events :
1973
-Incorporation of the Company.
1978
-the Company established its first plant at Taloja, Maharashtra.
1988
-the Company became a deemed public limited company.
1992
-the Company established its manufacturing facility in Mandwa, Maharashtra. This facility was converted into an API facility in 2005.
1998
-the Company established its Kachigam manufacturing facility in Gujarat.
2001
-Startronic Pharmachem Private Limited and Indo Propkem amalgamated with the Company.
2002
-the Company established its Amaliya manufacturing facility in Gujarat.
2003
-the Company set up its research and development facility at Taloja, Maharashtra.
2005
-the Company established its manufacturing facility in Baddi, Himachal Pradesh.
2006
-the anti-infective drug Taxim became the first drug in the Indian pharmaceutical industry to cross 1,000 million in terms of domestic sales in India (Source: IMS Research)
2007
-the Company established its manufacturing facility in Kumrek, Sikkim.
-the Company filed its first ANDA in the United States for the drug, Amlodipine.
-the Company shifted its Registered Office from Patna, Bihar to Mumbai, Maharashtra.
2009
-the Company acquired Pharmacor, a generic pharma company in Australia.
2010
-the Company acquired The PharmaNetwork, LLC, the holding company of Ascend Laboratories LLC.
2011
-the Company acquired Enzene Bio sciences Limited.
2012
-the Company acquired an API manufacturing facility in the United States.
2014
-the Company acquired the Clindac.
2015
-the Company acquired a formulation manufacturing facility in the United States.
Awards and achievements:
2002
-the Company was awarded the Pharma Business and Technology Excellence Award in 2002 as 'India's Most Esteemed Pharmaceutical Company'
2004
-the product Taxim was awarded the Pharma Business and Technology Excellence Award for successful brand in 2004
2005
-the Company was awarded the Overall Performance Award for Group B at the 5th Express Pharma Awards in 2005
2009
-the Company received a certificate of appreciation for outstanding export performance in the category of formulations by the Pharmaceuticals Export Promotion Council of India, supported by Ministry of Commerce and Industry, GOI
-the Company received the certificate of appreciation in the category of `Formulation Experts' by the Pharmaceuticals Export Promotion Council of India, supported by Ministry of Commerce and Industry, GOI
2013
-the Company was awarded the India's most admired pharma company award for 2013 at the 6th Annual Pharmaceutical Leadership Summit in 2013
2014
-the Product `Clavam' was awarded as the ` Brand of the Year' at the AWACS Award, 2014
2016
-Alkem's Mandva Plant successfully obtains the Establishment Inspection Report from the US FDA
-Alkem receives EIR from the US FDA for its Daman formulation facility
2017
-Marketing alliance with Haw Par to excusively market, sell and distribute Tiger Balam range of Product in India.
-Direct consumer marketing for pregakem and Livoerb
-Alkem received the Best Stand-out IR award 2017 by IR Society India in association with KPMG and Bloomberg
2018
-Revenue from the US market Crossed USD 200 mn in annual sales
-Brand 'Clavam' receiving Brand of the Year 2018 at AWACS AWARDS FOR Marketing Excellence
2019
-Crossed the reenue milestone of USD 1 billion
-Express Pharma Excellence Award at Pharma CXO Sumit 2019
-Alkem Laboratories takes over undertaking from Cachet Pharmaceuticals
2020
-Launch of Favipiravir in India under the brand name 'Alfluenza'
-CIO Conclave and Awards 2020 'In the category Best IT team of the Year'
2021
-Launch of Ibuprofen and Famotidine Tablets in the United States
-Launch of Perampanel Tablets in India unde the brand name 'Perampil'
-Alkem Parners with Tata Memorial Hospital
-Launch of Brivaracetam in India under the Brand name 'Brivasure'
-India's Best Wrokplaces in Biotechnology & Pharmaceutical Industry for the second consecutive year
2022
-Alkem signs license agreement with Harvard University's Office of Technology Development.
2023
-The Company has informed that ,the Company and Biosergen AB have entered into a co-development and license agreement for development and commercialization of Biosergen's novel polyene macrolide antifungal product BSG005 for the treatment of severe invasive fungal disease.
- The NCLT has approved the Scheme of Amalgamation for merger of M/s. Pharmasofttech Awacs Pvt. Ltd. into M/s. Pharmarack Technologies Pvt. Ltd. Both these Companies are subsidiaries of M/s Aarogya Bharat Digital LLP (earlier known as M/s. DigiHealth Technologies LLP). which in turn is a wholly-owned subsidiary of our investee entity i.e. M/s. ABCD Technologies LLP.
2024
-Alkem Laboratories launches MediSamvad, a digital knowledgesharing platform for healthcare professionals.
-Alkem Laboratories enters into a licensing agreement with US-based Sonnet BioTherapeutics to develop and commercialise its drug candidate for diabetic peripheral neuropathy in India.
-Alkem Foundation's walkathons in 5 cities to raise awareness about Alzheimer's disease.
-Alkem Laboratories signs a non-exclusive patent license agreement with Takeda to commercialise Vonoprazan in India.
2025
-Alkem launches probiotic 'DSS' the original De Simone formulation, in India for gut health management.
-Alkem and IIT Bombay announce strategic collaboration to set up advanced research centre for immunotherapeutics and regenerative medicines.
-Alkem launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer.
-Alkem launches Olesoft Trucera, an advanced ceramide-boosting moisturizing lotion for skin barrier repair.
-Alkem Laboratories launches generic empagliflozin and its combinations in India under the brand name 'Empanorm'
|